Gonadorelin


Generic Medicine Info
Contraindications
Pituitary adenoma. Pregnancy and lactation.
Special Precautions
Monitoring Parameters Obtain serum LH 15 minutes and immediately before administration, then 15, 30, 45, 60, and 120 minutes after administration.
Adverse Reactions
Significant: Haemorrhagic infarction (pituitary apoplexy). Rarely, hypersensitivity and anaphylactic reactions. Cardiac disorders: Rarely, tachycardia. Eye disorders: Rarely, erythema of eyelid. Gastrointestinal disorders: Rarely, nausea, abdominal discomfort. General disorders and administration site conditions: Pain, injection site reactions (e.g. induration, irritation, inflammation, erythema). Infections and infestations: Sepsis. Nervous system disorders: Rarely, headache, dizziness. Reproductive system and breast disorders: Menorrhagia. Respiratory, thoracic and mediastinal disorders: Rarely, bronchospasm. Skin and subcutaneous tissue disorders: Pruritus, rash. Rarely, urticaria. Vascular disorders: Thrombophlebitis. Rarely, flushing.
Drug Interactions
Androgens, estrogens, progestogens, or glucocorticoids may alter the response to gonadorelin. Gonadotropin levels may be transiently increased by spironolactone and to a lesser extent by methyldopa. Phenothiazines and dopamine antagonists may reduce response to gonadorelin. Gonadotropin levels may be suppressed by digoxin and oral contraceptives.
ATC Classification
V04CM01 - gonadorelin ; Belongs to the class of diagnostic agents used to test for fertility disturbances.
H01CA01 - gonadorelin ; Belongs to the class of gonadotropin-releasing hormones. Used in hypothalamic hormone preparations.
Disclaimer: This information is independently developed by CIMS based on gonadorelin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in